Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.57 |
| ▸ | FLT1 | P17948 | 8/20 | 0.49 |
| ▸ | TEK | Q02763 | 7/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 10/20 | 0.44 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | AURKA | O14965 | 4/20 | 0.43 |
| ▸ | FLT4 | P35916 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | LYN | P07948 | 2/20 | 0.43 |
| ▸ | ROS1 | P08922 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833228 | 0.90 | TEK (0.49) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3835826 | 0.89 | KDR (0.51) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3834274 | 0.88 | KDR (0.57) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3836431 | 0.88 | TEK (0.47) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3831528 | 0.85 | RET (0.61) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3834263 | 0.85 | RIPK1 (0.56) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3236450 | 0.84 | RET (0.44) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3239163 | 0.83 | CSF1R (0.41) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3238527 | 0.83 | RET (0.46) | RIPK1FLT1TEKRETKDR | |
| SCHEMBL3830022 | 0.83 | RIPK1 (0.56) | RIPK1KDRKITNTRK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682548-B1 | PYRIDOPYRIMIDINONES FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2009-09-23 | — | — | EP | claimed |
| US-7547695-B2 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2009-06-16 | — | — | US | claimed |
| US-20070099910-A1 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| US-7547695-B2 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20070203085-A1 | Methods For Interfering With Fibrosis | MERCK PATENT GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| US-20070191326-A1 | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| CN-1964705-A | Methods for interfering with fibrosis | MERCK PATENT GMBH (DE) | 2007-05-16 | — | — | CN | disclosed |
| US-20070099910-A1 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| CN-1929846-A | Methods for treating neuropsychiatric disorders comprising modulating glutamate receptors with modulators of serum and glucocorticoid inducible kinases | MERCK PATENT GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
| CN-1929831-A | Methods for altering insulin secretion | MERCK PATENT GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203085-A1 | Methods For Interfering With Fibrosis | MMP1, SERPINA6, HDGF | RIPK1 1761/4885FLT1 2905/4885TEK 1272/4885 |
| US-20070099910-A1 | Pyridopyrimidinones | TIE1, FER, FLT1 | RIPK1 273/4885FLT1 3/4885TEK 9/4885 |
| US-20070191326-A1 | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases | GRIK2, GRIK1, GRM2 | RIPK1 207/4885FLT1 4570/4885TEK 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.